Fortress Biotech, Inc. (NASDAQ:FBIO - Get Free Report) CFO David Jin purchased 15,000 shares of the company's stock in a transaction on Tuesday, November 17th. The shares were purchased at an average price of $1.72 per share, for a total transaction of $25,800.00. Following the purchase, the chief financial officer owned 1,667,761 shares in the company, valued at approximately $2,868,548.92. The trade was a 0.91% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
David Jin also recently made the following trade(s):
- On Thursday, November 19th, David Jin purchased 7,605 shares of Fortress Biotech stock. The shares were bought at an average cost of $1.87 per share, for a total transaction of $14,221.35.
- On Wednesday, November 18th, David Jin acquired 25,000 shares of Fortress Biotech stock. The stock was purchased at an average cost of $1.91 per share, with a total value of $47,750.00.
Fortress Biotech Price Performance
Shares of FBIO stock traded down $0.11 during trading hours on Thursday, hitting $1.78. 194,841 shares of the company's stock were exchanged, compared to its average volume of 586,980. The company has a quick ratio of 3.83, a current ratio of 2.93 and a debt-to-equity ratio of 0.10. The firm has a 50 day moving average of $2.08 and a two-hundred day moving average of $2.70. The firm has a market cap of $60.16 million, a P/E ratio of 0.78 and a beta of 1.27. Fortress Biotech, Inc. has a fifty-two week low of $1.64 and a fifty-two week high of $4.53.
Fortress Biotech (NASDAQ:FBIO - Get Free Report) last released its earnings results on Friday, November 13th. The biopharmaceutical company reported ($0.23) EPS for the quarter, topping analysts' consensus estimates of ($0.27) by $0.04. Fortress Biotech had a net margin of 143.04% and a return on equity of 61.84%. The business had revenue of $19.16 million during the quarter, compared to analysts' expectations of $21.57 million.
Hedge Funds Weigh In On Fortress Biotech
Several hedge funds and other institutional investors have recently made changes to their positions in FBIO. Marshall Wace LLP acquired a new position in shares of Fortress Biotech during the third quarter worth about $462,000. Renaissance Technologies LLC raised its holdings in Fortress Biotech by 22.8% in the first quarter. Renaissance Technologies LLC now owns 99,590 shares of the biopharmaceutical company's stock valued at $278,000 after acquiring an additional 18,490 shares in the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in Fortress Biotech in the second quarter valued at approximately $47,000. Hedge funds and other institutional investors own 96.51% of the company's stock.
Recent Fortress Biotech Headlines
Investors following FBIO have been watching these headlines:
- Positive Sentiment: CEO Lindsay Rosenwald bought 136,723 shares across three transactions from November 17–19, spending about $253,000. CFO David Jin also bought 47,605 shares over the same period for approximately $88,000. These open-market purchases increased both executives’ holdings and may signal confidence in the company. CEO SEC filing CFO SEC filing
- Neutral Sentiment: HC Wainwright forecast EPS of $2.66 for FY2026 and $2.37 for FY2027. The report also estimated a Q4 2026 loss of $0.15 per share; the articles did not provide a rating change or explain the basis for the annual forecasts. Analyst insights article
Wall Street Analysts Forecast Growth
Several analysts have recently commented on the stock. Weiss Ratings lowered shares of Fortress Biotech from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Friday, October 23rd. Wall Street Zen downgraded shares of Fortress Biotech from a "strong-buy" rating to a "hold" rating in a research note on Saturday, August 15th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Fortress Biotech presently has an average rating of "Hold" and an average price target of $17.00.
Check Out Our Latest Research Report on FBIO
About Fortress Biotech
(
Get Free Report)
Fortress Biotech, Inc. is a biopharmaceutical company that develops and commercializes prescription medicines through a network of subsidiaries and affiliated companies. Its approach includes advancing drug candidates, acquiring or licensing development and commercialization rights, and building companies around selected products and programs. The company's activities span areas including oncology, dermatology, rare diseases and immunology. Its portfolio has included marketed dermatology medicines such as Qbrexza, Amzeeq and Zilxi, as well as investigational therapies at various stages of development.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Fortress Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fortress Biotech wasn't on the list.
While Fortress Biotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.